

**PROGRESSIVE'S EVENING STROLL**

**DATE: 24 April, 2025**

**Market Snapshot:**

The lacklustre monthly expiry session ended on a subdued note, with the Index closing lower at 24,246.70 with a loss of 82.25 points. Sector-wise, Pharma and Metal emerged as the top performers, while Realty and FMCG witnessed the most significant corrections. Mid and Smallcap segments managed to outperform the Frontline Index, showing relative strength.

**HOW THE DAY TRENDED**



**INDICES**

Index	Close	Points	%Chg.
Sensex	79801.43	(315.06)	(0.39)
Nifty50	24246.70	(82.25)	(0.34)
Nifty Midcap 100	54969.85	(71.25)	(0.13)
Nifty Small Cap 100	16963.50	(6.25)	(0.04)

**SECTORAL GAINERS / LOSERS**

Sectors	Close	Points	%Chg.
NIFTY PHARMA	21974.60	235.65	1.08
NIFTY METAL	8753.30	16.00	0.18
NIFTY FMCG	56887.55	(610.35)	(1.06)
NIFTY REALTY	884.15	(12.60)	(1.41)

**NIFTY TOP GAINERS / LOSERS**

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
INDUSIND BANK	819.75	3.22	HUL	2325.30	(4.06)
ULTRATECH	12159.00	1.76	BHARTI AIRTEL	1845.60	(1.91)
GRASIM	2729.20	1.62	EICHER MOTORS	5650.50	(1.56)
TATA MOTORS	668.35	1.28	ICICI BANK	1402.70	(1.52)

**INDICES LEVELS FOR April 25, 2025**

Nifty (future)		Bank Nifty (future)	
Resistance	24500	Resistance	55660
Support	24200	Support	54950



**PROGRESSIVE'S EVENING STROLL**

**DATE: 24 April, 2025**

**KEY TAKEAWAYS OF THE DAY**

◆ **Vascon Engineers gets Lol for a project worth Rs2255mn from Royal Rides:**

The company has bagged an order totaling Rs2255mn from Royal Rides. The company has received a Lol from Royal Rides for construction of two terminal buildings along with Ropeway Tower works at Panaji and Reis Magos, Goa. The contract also entails other site development work at both the sites. The infrastructure construction company needs to complete the work which has been awarded on "design and build basis" within 36 months from the date of the Lol.

◆ **Biocon approves Rs45bn fund raise and increases authorized share capital to Rs7bn:**

The company has approved raising up to Rs45bn through the issue of securities via methods including QIP, rights issues, or other permissible routes, in one or more tranches. The board has also approved an increase in the authorised share capital of the company from Rs6.25bn to Rs7bn, along with a corresponding amendment to the capital clause in its MoA. The change will also be subject to shareholder and regulatory approvals.

◆ **BPCL, GPS Renewables sign JV to set up compressed biogas plants across India:**

The company has signed a JV agreement with GPS Renewables to establish a network of CBG plants across India, in a move aimed at bolstering the country's renewable energy infrastructure and accelerating BPCL's Net Zero goals. The JV will focus on converting organic biomass waste into CBG, a clean and renewable energy source, through advanced waste-to-energy technologies.

◆ **Panacea Biotec bags new Rs440mn order from UNICEF:**

The company has secured an additional contract from the United Nations International Children's Emergency Fund (UNICEF), an international entity, for the supply of 40mn doses (2mn vials) of its bivalent oral polio vaccine (bOPV). This significant order, valued at approximately USD5.2mn (around Rs440mn), is slated for execution in the third quarter of calendar year 2025 and will necessitate an amendment to the existing Long-Term Arrangement between UNICEF and the Company.

◆ **ROHL continues expansion in Maharashtra; launches Regenta Bharti Resort in Mahabaleshwar:**

The company inaugurated its 14th property in the state with the launch of Regenta Bharti Resort in the picturesque hill station of Mahabaleshwar. The property will be managed by Royal Orchid Hotels based on a management contract under the brand "Regenta" offering guests a seamless experience in the tranquil vibes of Mahabaleshwar.

◆ **Aurobindo Pharma WoS gets USFDA nod for Dasatinib Tablets; USD1.8bn market:**

The WoS (Eugia Pharma Specialities) of Aurobindo Pharma has received USFDA final approval to manufacture and market Dasatinib Tablets, 20/50/70/80/100/140mg. According to IQVIA, the tablets have an estimated market size of USD1.8bn for twelve months ending February 2025. The product is expected to be launched in Q1FY26.

**Source: Media Reports**



## DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

## Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

### Compliance Officer:

Ms. Neha Oza,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

### Grievance Officer:

Email: grievancecell@progressiveshares.com

